Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 3M-052-AF Clear all

Conditions: COVID-19 Respiratory Infection, SARS CoV 2 Infection, COVID-19 Vaccine
Interventions: CoV-RBD-scNP-001 and 3M-052-AF; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Zika, Zika Virus Infection
Interventions: VLA1601, CpG 1018®, 3M-052-AF; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Sioux City, Iowa • Lincoln, Nebraska + 1 more

Conditions: HIV Infections
Interventions: BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more

Conditions: HIV
Interventions: 426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant, Aluminum hydroxide suspension (Alum) adjuvant, Diluent; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: San Francisco, California • Atlanta, Georgia • Decatur, Georgia + 2 more

Conditions: HIV-1
Interventions: CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 19 more

Conditions: HIV-1-infection
Interventions: INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee

Conditions: HIV Infections
Interventions: CH505 TF chTrimer, 3M-05-AF, Aluminum hydroxide suspension; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Decatur, Georgia • Boston, Massachusetts • Nashville, Tennessee

Conditions: HIV-1-infection
Interventions: 426c.Mod.Core-C4b 30 mcg, 426c.Mod.Core-C4b 100 mcg, 426c.Mod.Core-C4b 300 mcg, Placebo, BG505; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 3 more

Conditions: HIV
Interventions: CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), ACU-026-001-1 (labeled as empty LNP); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee

Conditions: Hiv
Interventions: V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg, Alum 500 mcg, V3G CH848 mRNA-Tr2 50mcg, ACU-026-001-1 2.0mg, V3G CH848 Pr-NP1 100mcg; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: HIV Infections
Interventions: sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571, 3M-052-AF, Alum; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts

Conditions: HIV
Interventions: 16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more

Conditions: HIV-1-infection
Interventions: 3M-052-AF + Alum, UVAX-1107, UVAX-1197; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Birmingham, Alabama • New York, New York • Rochester, New York + 1 more

Conditions: Chronic HIV Infection
Interventions: 426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 4 more

Search by objective public record fields.

Pancoronavirus Vaccine Study in Healthy Adults

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies